Alimera Sciences Re-Files for IPO
11/2/2009 8:11:26 AM
More...
|
Alimera Sciences Reports Safety and Efficacy Results From the 18-Month Interim Readout of the Human PK Iluvien(R) Study
9/29/2009 10:37:24 AM
More...
|
Alimera Sciences Begins Pilot Study of Iluvien(R) in Patients With Macular Edema Secondary to Retinal Vein Occlusion
9/24/2009 8:53:16 AM
More...
|
Alimera Sciences Closes $5 Million in Extended Series C Financing
8/27/2009 7:29:14 AM
More...
|
Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
5/4/2009 9:39:00 AM
More...
|
Alimera Sciences Cancels IPO
4/9/2009 7:46:45 AM
More...
|
Alimera Sciences' Iluvien(TM) Phase 3 Studies for DME Pass Final DSMB Review Prior to October Readout
4/8/2009 11:01:46 AM
More...
|
pSivida Corp (PSDV) And Alimera Sciences Reports Favorable 12-Month Interim Safety and Efficacy Results from Iluvien(TM) Human PK Study
3/12/2009 10:44:25 AM
More...
|
Alimera Sciences Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
3/12/2009 10:26:53 AM
More...
|
Alimera Sciences Begins Pilot Study to Assess Safety and Efficacy of Iluvien(TM) in Patients With Bilateral Geographic Atrophy Due to AMD
12/11/2008 8:27:18 AM
More...
|
|